Skip to content
10-Q

Quarterly Report

Anika Therapeutics, Inc. ANIK

0001171843-26-002852

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 21, 2026 13.31M sh
Shares Diluted Q1 2026 · Mar 31, 2026 13.53M sh
Shares Diluted Q1 2026 · Mar 31, 2025 14.3M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $8.69M
Stock Repurchased Q1 2026 · Mar 31, 2025 $3.97M
Capex Q1 2026 · Mar 31, 2026 $1.43M
Capex Q1 2026 · Mar 31, 2025 $2.82M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.85M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$130K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $41.02M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $57.48M
Stockholders Equity Q1 2026 · Mar 31, 2026 $133.9M
Stockholders Equity Q1 2026 · Dec 31, 2025 $143.47M
Stockholders Equity Q1 2026 · Mar 31, 2025 $148.4M
Stockholders Equity Q1 2026 · Dec 31, 2024 $153.99M
Current Liabilities Q1 2026 · Mar 31, 2026 $20.97M
Current Liabilities Q1 2026 · Dec 31, 2025 $21.91M
Current Assets Q1 2026 · Mar 31, 2026 $93.56M
Current Assets Q1 2026 · Dec 31, 2025 $103.36M
Total Assets Q1 2026 · Mar 31, 2026 $179.39M
Total Assets Q1 2026 · Dec 31, 2025 $190.27M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.37
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.34
Eps Basic Q1 2026 · Mar 31, 2026 −$0.37
Eps Basic Q1 2026 · Mar 31, 2025 −$0.34
Sga Expense Q1 2026 · Mar 31, 2026 $17.77M
Sga Expense Q1 2026 · Mar 31, 2025 $12.91M
Rd Expense Q1 2026 · Mar 31, 2026 $6.71M
Rd Expense Q1 2026 · Mar 31, 2025 $6.06M
Net Income Q1 2026 · Mar 31, 2026 −$5.06M
Net Income Q1 2026 · Mar 31, 2025 −$4.87M
Operating Income Q1 2026 · Mar 31, 2026 −$5.49M
Operating Income Q1 2026 · Mar 31, 2025 −$4.28M
Gross Profit Q1 2026 · Mar 31, 2026 $19M
Gross Profit Q1 2026 · Mar 31, 2025 $14.68M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $10.62M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $11.49M
Revenue Q1 2026 · Mar 31, 2026 $29.61M
Revenue Q1 2026 · Mar 31, 2025 $26.17M